

**BIOCON PHARMA UK LIMITED****BALANCE SHEET AS AT MARCH 31,2022****(All amounts in GBP, except share data and per share data, unless otherwise stated)**

	<u>Note</u>	<u>March 31,2022</u>	<u>March 31, 2021</u>
<b>ASSETS</b>			
<b>Non current assets</b>			
Intangible assets under development		90,163	-
<b>Current assets</b>			
Financial assets			
(i) Cash and cash equivalents	3	82,705	1,00,435
(ii) Other financial assets	4	5,19,502	9,674
Other current assets	5	5,514	6,612
<b>Total current assets</b>		<b>6,07,721</b>	<b>1,16,721</b>
<b>TOTAL</b>		<b>6,97,884</b>	<b>1,16,721</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Equity share capital	6(a)	3,50,000	3,50,000
Preference share capital	6(a)	13,27,000	6,57,000
Other equity	6(b)	(10,16,160)	(10,16,516)
<b>Total equity</b>		<b>6,60,840</b>	<b>(9,516)</b>
<b>Current liabilities</b>			
Financial liabilities			
(i) Trade payables	7	22,431	1,11,819
Other current liabilities	8	14,613	14,418
<b>Total current liabilities</b>		<b>37,044</b>	<b>1,26,237</b>
<b>TOTAL</b>		<b>6,97,884</b>	<b>1,16,721</b>

The accompanying notes are an integral part of the financial statements.

*for and on behalf of the Board of Directors of Biocon Pharma UK Limited*

**Kiran Mazumdar-Shaw**  
*Director*  
DIN: 00347229

**John Shaw**  
*Director*  
DIN: 00347250

**BIOCON PHARMA UK LIMITED****STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31,2022****(All amounts in GBP, except share data and per share data, unless otherwise stated)**

	<u>Note</u>	<u>Year ended</u> <u>March 31, 2022</u>	<u>Year ended</u> <u>March 31, 2021</u>
<b>Income</b>			
Other income		699	-
<b>Total income</b>		<b>699</b>	<b>-</b>
<b>Expenses</b>			
Employee benefits expense	9	-	3,71,371
Finance Cost	12	-	-
Other expenses	10	343	1,45,812
<b>Total expenses</b>		<b>343</b>	<b>5,17,183</b>
<b>Profit/(Loss) before tax</b>		<b>356</b>	<b>(5,17,183)</b>
<b>Tax expenses</b>			
Current tax		-	-
Deferred tax		-	-
<b>Total tax expense</b>		<b>-</b>	<b>-</b>
<b>(Loss) for the year/period</b>		<b>356</b>	<b>(5,17,183)</b>

The accompanying notes are an integral part of the financial statements.

*for and on behalf of the Board of Directors of Biocon Pharma UK Limited***Kiran Mazumdar-Shaw***Director*

DIN: 00347229

**John Shaw***Director*

DIN: 00347250

**BIOCON PHARMA UK LIMITED**  
**STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED MARCH 31,2022**  
**(All amounts in GBP, except share data and per share data, unless otherwise stated)**

<b>A. Equity share capital</b>	<b>March 31,2022</b>	<b>March 31, 2021</b>
Opening balance	3,50,000	-
<b>Closing balance</b>	<b>3,50,000</b>	<b>3,50,000</b>

<b>B. Preference share capital</b>	<b>March 31,2022</b>	<b>March 31, 2021</b>
Opening balance	-	-
Issue of share capital during the year	13,27,000	-
<b>Closing balance</b>	<b>13,27,000</b>	<b>-</b>

**C. Other equity**

Particulars	Other equity	Total other equity
	Retained earnings	
<b>Balance as at April 01, 2020</b>	<b>(4,99,333)</b>	<b>(4,99,333)</b>
Loss for the period	(5,17,183)	(5,17,183)
Other comprehensive income	-	-
<b>Total comprehensive income for the period</b>	<b>(5,17,183)</b>	<b>(5,17,183)</b>
<b>Balance as at March 31, 2021</b>	<b>(10,16,516)</b>	<b>(10,16,516)</b>
Share application money pending allotment		
Loss for the year	356	356
Other comprehensive income	-	-
<b>Total comprehensive income for the year</b>	<b>356</b>	<b>356</b>
<b>Balance as at March 31,2022</b>	<b>(10,16,160)</b>	<b>(10,16,160)</b>

The accompanying notes are an integral part of the financial statements.

*for and on behalf of the Board of Directors of Biocon Pharma UK Limited*

**Kiran Mazumdar-Shaw**  
*Director*  
DIN: 00347229

**John Shaw**  
*Director*  
DIN: 00347250

**BIOCON PHARMA UK LIMITED**  
**STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED MARCH 31,2022**  
(All amounts are in GBP, except share data and per share data, unless otherwise stated)

	Year ended March 31, 2022	Year ended March 31, 2021
<b>I Cash flows from operating activities</b>		
Loss after tax	356	(5,17,183)
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Interest expense	-	-
Operating profit before working capital changes	<b>356</b>	<b>(5,17,183)</b>
<b>Movements in working capital</b>		
(Increase)/Decrease in loans and advances and other assets	(5,08,730)	(13,179)
Increase/ (decrease) in trade payable, other liabilities and provisions	(89,193)	(73,870)
<b>Cash generated from operations</b>	<b>(5,97,567)</b>	<b>(6,04,232)</b>
Direct taxes paid, net	-	-
<b>Net cash flow from operating activities</b>	<b>(5,97,567)</b>	<b>(6,04,232)</b>
<b>II Cash flows from investing activities</b>		
Purchase of tangible assets	(90,163)	-
<b>Net cash flow from / (used) in investing activities</b>	<b>(90,163)</b>	-
<b>III Cash flows from financing activities</b>		
Proceeds from long-term borrowings	-	1,00,000
Repayment of long-term borrowings	-	(1,89,682)
Proceeds from issuance of share capital	6,70,000	6,57,000
Interest paid	-	(2,109)
<b>Net cash flow used in financing activities</b>	<b>6,70,000</b>	<b>5,65,209</b>
<b>IV Net increase in cash and cash equivalents (I + II + III)</b>	<b>(17,730)</b>	<b>(39,023)</b>
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-	-
VI Cash and cash equivalents at the beginning of the period	1,00,435	1,39,458
<b>VII Cash and cash equivalents at the end of the period (IV + V + VI)</b>	<b>82,705</b>	<b>1,00,435</b>
<b>Reconciliation of cash and cash equivalents as per statement of cash flow</b>		
<b>Cash and cash equivalents</b>		
Balances with banks - on current accounts	82,705	1,00,435
Cash on hand	-	-
	<b>82,705</b>	<b>1,00,435</b>
Book overdraft	-	-
<b>Total cash and cash equivalents [refer note 3]</b>	<b>82,705</b>	<b>1,00,435</b>

The accompanying notes are an integral part of the financial statements.

*for and on behalf of the Board of Directors of Biocon Pharma UK Limited*

**Kiran Mazumdar-Shaw**  
Director  
DIN: 00347229

**John Shaw**  
Director  
DIN: 00347250

**BIOCON PHARMA UK LIMITED**

**Notes to the financial statements for the period ended March 31,2022**

(All amounts in GBP, except share data and per share data, unless otherwise stated)

	<u>March 31,2022</u>	<u>March 31, 2021</u>
<b>3. Cash and cash equivalents</b>		
Balances with banks:		
On current accounts	82,705	1,00,435
<b>Total cash and cash equivalent</b>	<u>82,705</u>	<u>1,00,435</u>
<b>4. Other financial assets</b>		
<b>(a) Current</b>		
Others	5,19,502	9,674
	<u>5,19,502</u>	<u>9,674</u>
<b>5. Other assets</b>		
<b>(a) Current</b>		
Advances to suppliers	-	-
Prepayments	-	-
Balances with statutory / government authorities	5,514	6,612
	<u>5,514</u>	<u>6,612</u>
<b>6(a). Equity share capital</b>		
<b>Issued, subscribed and fully paid-up</b>		
350,000 (March 31, 2020: 350,000) ordinary shares of GBP 1 per share	3,50,000	3,50,000
13,27,000 (March 31, 2020: 6,57,000) ordinary shares of GBP 1 per share	13,27,000	6,57,000
<b>(i) Reconciliation of the shares outstanding at the beginning and at the end of the reporting period</b>		
<b>Equity shares</b>	<b>March 31,2022</b>	<b>March 31, 2021</b>
	<b>No.</b>	<b>GBP</b>
At the beginning of the year	3,50,000	3,50,000
Issued during the year	-	-
<b>Outstanding at the end of the year</b>	<u>3,50,000</u>	<u>3,50,000</u>
<b>Preference shares</b>	<b>March 31,2022</b>	<b>March 31, 2021</b>
	<b>No.</b>	<b>GBP</b>
At the beginning of the year	6,57,000	6,57,000
Issued during the year	6,70,000	6,70,000
<b>Outstanding at the end of the year</b>	<u>13,27,000</u>	<u>13,27,000</u>
<b>6(b). Other equity</b>		
<b>Retained earnings</b>		
The amount that can be distributed by the Company as dividends to its equity shareholders.		
	<u>March 31,2022</u>	<u>March 31, 2021</u>
<b>7. Trade payables</b>		
Trade payables	22,431	1,11,819
	<u>22,431</u>	<u>1,11,819</u>
<b>8. Other liabilities</b>		
<b>Current</b>		
Statutory taxes and dues payable	14,613	14,418
	<u>14,613</u>	<u>14,418</u>

**BIOCON PHARMA UK LIMITED****Notes to the financial statements for the period ended March 31,2022****(All amounts in GBP, except share data and per share data, unless otherwise stated)**

	<b>Year ended March 31, 2022</b>	<b>Year ended March 31, 2021</b>
<b><u>11. Other income</u></b>		
Foreign exchange gain, net	-	-
Other Income	699	
	<b>699</b>	<b>-</b>
<b><u>9. Employee benefits expense</u></b>		
Salaries, wages and bonus	-	3,09,730
Employee stock compensation expense	-	11,881
Staff welfare expenses	-	49,760
	<b>-</b>	<b>3,71,371</b>
<b><u>12. Finance costs</u></b>		
Interest on Loan	-	-
	<b>-</b>	<b>-</b>
<b><u>10. Other expenses</u></b>		
Communication expenses	-	1,466
Travelling and conveyance	-	381
Professional charges	-	96,629
Payments to auditors[refer note (a) below]	-	-
Power and fuel	-	-
Insurance	-	-
Rates, taxes and fees, net of refunds of taxes	300	-
Research & development expenses	-	44,955
Foreign exchange loss, net	43	3
	<b>343</b>	<b>1,45,812</b>

&lt;THIS SPACE HAS BEEN INTENTIONALLY LEFT BLANK&gt;